News

Thermo Fisher: New Headwinds Could Delay The Industry's Recovery
Thermo Fisher shows signs of post-COVID recovery, but modest growth, valuation risks, and macro pressures warrant caution.
24/7 Wall St. on MSN7d
4 High-Yield Blue-Chip Pharmaceutical Giants Offer Huge Total Return Potential
After underperforming the overall market for the past few years, large-cap pharmaceutical stocks may now be positioned to ...
C&EN6mon
Cell and gene therapy: The next frontier in pharmaceutical services
The US Food and Drug Administration has approved only a handful of cell and gene therapies, but over 1,000 candidates are now in clinical trials, creating a demand for pharmaceutical services that ...
Insider Media17h
492-strong Welsh pharma firm posts turnover and profits fall amid client demand decrease
A 492-strong Cardiff-based pharmaceutical firm has posted a fall in turnover and profits in its latest year amid a decrease ...
ZAWYA19h
Egypt’s PM reviews efforts to support local pharmaceutical industry
Madbouly affirmed the government’s interest in providing all necessary support for the growth and localisation of this vital industry ...
C&EN1y
Private equity ramps up in pharmaceutical services
Industry observers, concerned about FIS’s future, questioned whether the Ferrari family, its owner, could continue to run a company that had grown to over 2,000 employees and 300 customers.
Reuters1y
West Pharmaceutical Services Inc | Reuters
West Pharmaceutical Services forecast full-year results below analysts' estimates on Thursday after the company missed fourth-quarter revenue expectations, hurt by weak demand for its medical ...
Nasdaq1mon
Frost & Sullivan Released Report: "2025 China Pharmaceutical ... - Nasdaq
Frost& Sullivan released the "2025 China Pharmaceutical CDMO Industry Insight Blue Book", a comprehensive analysis of the evolution and strategic trajectory of China's pharmaceutical Contract ...